Chemical Tuning Enhances Both Potency Toward Nrf2 and In Vitro Therapeutic Index of Triterpenoids
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chemical Tuning Enhances Both Potency Toward Nrf2 and In Vitro Therapeutic Index of Triterpenoids
Authors
Keywords
-
Journal
TOXICOLOGICAL SCIENCES
Volume 140, Issue 2, Pages 462-469
Publisher
Oxford University Press (OUP)
Online
2014-05-06
DOI
10.1093/toxsci/kfu080
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Extinguished BEACON of Bardoxolone: Not a Monday Morning Quarterback Story
- (2013) John A. Tayek et al. AMERICAN JOURNAL OF NEPHROLOGY
- Role of Nrf2 in Oxidative Stress and Toxicity
- (2013) Qiang Ma Annual Review of Pharmacology and Toxicology
- The fumaric acid ester BG-12: a new option in MS therapy
- (2013) De-Hyung Lee et al. Expert Review of Neurotherapeutics
- Role of Nrf2 in protection against acute kidney injury
- (2013) Luke M. Shelton et al. KIDNEY INTERNATIONAL
- Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease
- (2013) Stacey Ruiz et al. KIDNEY INTERNATIONAL
- Could problems with bardoxolone methyl have been predicted?
- (2013) Peter Rossing Nature Reviews Nephrology
- Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
- (2013) Dick de Zeeuw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sulforaphane: translational research from laboratory bench to clinic
- (2013) Christine A Houghton et al. NUTRITION REVIEWS
- Toward clinical application of the Keap1–Nrf2 pathway
- (2013) Takafumi Suzuki et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Bardoxolone Brings Nrf2-Based Therapies to Light
- (2012) Donna D. Zhang ANTIOXIDANTS & REDOX SIGNALING
- The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation
- (2012) Holly K. Bryan et al. BIOCHEMICAL PHARMACOLOGY
- A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
- (2012) D. S. Hong et al. CLINICAL CANCER RESEARCH
- Suppression of the Nrf2-Dependent Antioxidant Response by Glucocorticoids and 11β-HSD1-Mediated Glucocorticoid Activation in Hepatic Cells
- (2012) Denise V. Kratschmar et al. PLoS One
- Screening for natural chemoprevention agents that modify human Keap1
- (2011) Chenqi Hu et al. ANALYTICAL BIOCHEMISTRY
- Modification of Keap1 Cysteine Residues by Sulforaphane
- (2011) Chenqi Hu et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Managing the challenge of chemically reactive metabolites in drug development
- (2011) B. Kevin Park et al. NATURE REVIEWS DRUG DISCOVERY
- Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
- (2011) Pablo E. Pergola et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification and Characterization of Novel Nrf2 Inducers Designed to Target the Intervening Region of Keap1
- (2010) Jian H. Wu et al. Chemical Biology & Drug Design
- Potency ranking of triterpenoids as inducers of a cytoprotective enzyme and as inhibitors of a cellular inflammatory response via their electron affinity and their electrophilicity index
- (2010) René V. Bensasson et al. CHEMICO-BIOLOGICAL INTERACTIONS
- A dicyanotriterpenoid induces cytoprotective enzymes and reduces multiplicity of skin tumors in UV-irradiated mice
- (2008) Albena T. Dinkova-Kostova et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The Nrf2–Keap1 defence pathway: Role in protection against drug-induced toxicity
- (2007) Ian M. Copple et al. TOXICOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started